| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spinal Cord Ischemia | 23 | 2022 | 56 | 10.050 |
Why?
|
| Aorta, Thoracic | 38 | 2025 | 263 | 9.180 |
Why?
|
| Reperfusion Injury | 22 | 2021 | 272 | 6.370 |
Why?
|
| Blood Vessel Prosthesis Implantation | 18 | 2025 | 197 | 6.200 |
Why?
|
| Aortic Aneurysm, Thoracic | 20 | 2025 | 127 | 5.720 |
Why?
|
| Spinal Cord | 20 | 2022 | 355 | 5.380 |
Why?
|
| Aortic Aneurysm | 11 | 2025 | 66 | 4.200 |
Why?
|
| Cardiac Surgical Procedures | 31 | 2024 | 509 | 3.980 |
Why?
|
| Aortic Valve | 27 | 2021 | 348 | 3.730 |
Why?
|
| Erythropoietin | 7 | 2018 | 88 | 3.510 |
Why?
|
| Vascular Surgical Procedures | 11 | 2025 | 295 | 3.310 |
Why?
|
| Paraplegia | 14 | 2023 | 57 | 3.290 |
Why?
|
| Spinal Cord Injuries | 10 | 2022 | 194 | 3.100 |
Why?
|
| Heart Valve Diseases | 10 | 2020 | 152 | 2.740 |
Why?
|
| Diazoxide | 5 | 2021 | 23 | 2.670 |
Why?
|
| Thoracic Surgery | 12 | 2022 | 123 | 2.450 |
Why?
|
| Cerebrovascular Circulation | 7 | 2022 | 228 | 2.350 |
Why?
|
| Aortic Diseases | 8 | 2021 | 114 | 2.230 |
Why?
|
| Receptors, Erythropoietin | 4 | 2018 | 20 | 2.210 |
Why?
|
| Postoperative Complications | 26 | 2025 | 2481 | 2.160 |
Why?
|
| Heart Valve Prosthesis Implantation | 11 | 2020 | 177 | 2.080 |
Why?
|
| Aorta | 12 | 2024 | 408 | 2.020 |
Why?
|
| Neuroprotective Agents | 5 | 2018 | 121 | 1.880 |
Why?
|
| Dexmedetomidine | 5 | 2014 | 44 | 1.760 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 4 | 2014 | 25 | 1.690 |
Why?
|
| Hypothermia, Induced | 5 | 2022 | 76 | 1.680 |
Why?
|
| Surgeons | 5 | 2022 | 264 | 1.650 |
Why?
|
| Cyclohexanecarboxylic Acids | 8 | 2008 | 22 | 1.630 |
Why?
|
| Thoracic Surgical Procedures | 6 | 2024 | 70 | 1.520 |
Why?
|
| Purines | 8 | 2008 | 172 | 1.500 |
Why?
|
| Subclavian Artery | 5 | 2020 | 28 | 1.460 |
Why?
|
| Coronary Artery Bypass | 9 | 2025 | 224 | 1.360 |
Why?
|
| Cardiology | 5 | 2019 | 266 | 1.340 |
Why?
|
| Circulatory Arrest, Deep Hypothermia Induced | 6 | 2022 | 25 | 1.330 |
Why?
|
| Aortic Valve Stenosis | 13 | 2021 | 219 | 1.310 |
Why?
|
| Neuroprotection | 3 | 2017 | 39 | 1.230 |
Why?
|
| Heart Arrest, Induced | 4 | 2021 | 31 | 1.220 |
Why?
|
| Humans | 158 | 2025 | 129847 | 1.220 |
Why?
|
| Toll-Like Receptor 4 | 11 | 2020 | 264 | 1.210 |
Why?
|
| Aortic Valve Insufficiency | 5 | 2018 | 46 | 1.200 |
Why?
|
| Microglia | 4 | 2013 | 234 | 1.150 |
Why?
|
| Mitral Valve | 6 | 2020 | 86 | 1.140 |
Why?
|
| Endovascular Procedures | 7 | 2023 | 301 | 1.130 |
Why?
|
| Heart Transplantation | 10 | 2024 | 722 | 1.070 |
Why?
|
| Lung Transplantation | 8 | 2024 | 290 | 1.030 |
Why?
|
| Dissection | 4 | 2020 | 51 | 1.000 |
Why?
|
| Mice, Inbred C57BL | 19 | 2021 | 5468 | 0.990 |
Why?
|
| Adenosine A2 Receptor Agonists | 6 | 2007 | 21 | 0.930 |
Why?
|
| Ischemia | 5 | 2021 | 405 | 0.930 |
Why?
|
| Cardiopulmonary Bypass | 9 | 2022 | 203 | 0.920 |
Why?
|
| Up-Regulation | 6 | 2020 | 836 | 0.900 |
Why?
|
| Heart Diseases | 5 | 2019 | 352 | 0.890 |
Why?
|
| Intraoperative Neurophysiological Monitoring | 2 | 2021 | 21 | 0.890 |
Why?
|
| Coronary Artery Disease | 4 | 2025 | 680 | 0.880 |
Why?
|
| Disease Models, Animal | 17 | 2021 | 4077 | 0.870 |
Why?
|
| Elective Surgical Procedures | 1 | 2025 | 165 | 0.860 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 2 | 2013 | 17 | 0.840 |
Why?
|
| Male | 85 | 2025 | 63759 | 0.830 |
Why?
|
| Receptor, Adenosine A2A | 6 | 2008 | 20 | 0.830 |
Why?
|
| Mice | 24 | 2021 | 16983 | 0.750 |
Why?
|
| Troponin I | 1 | 2022 | 75 | 0.750 |
Why?
|
| Perfusion | 6 | 2024 | 197 | 0.750 |
Why?
|
| Periodicals as Topic | 2 | 2015 | 204 | 0.740 |
Why?
|
| STAT3 Transcription Factor | 3 | 2018 | 194 | 0.740 |
Why?
|
| Animals | 41 | 2021 | 35409 | 0.730 |
Why?
|
| Retrospective Studies | 40 | 2025 | 14553 | 0.730 |
Why?
|
| Treatment Outcome | 27 | 2024 | 10241 | 0.720 |
Why?
|
| Disease Management | 1 | 2025 | 592 | 0.700 |
Why?
|
| Anesthesiology | 3 | 2018 | 63 | 0.690 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2020 | 13 | 0.670 |
Why?
|
| Calcinosis | 6 | 2018 | 233 | 0.670 |
Why?
|
| Aortic Rupture | 2 | 2018 | 25 | 0.670 |
Why?
|
| Signal Transduction | 14 | 2020 | 4935 | 0.670 |
Why?
|
| Decision Support Techniques | 1 | 2024 | 401 | 0.670 |
Why?
|
| Carotid Artery, Common | 1 | 2020 | 35 | 0.660 |
Why?
|
| Beauty | 1 | 2020 | 19 | 0.660 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2020 | 43 | 0.660 |
Why?
|
| Nervous System Diseases | 2 | 2021 | 252 | 0.650 |
Why?
|
| Middle Aged | 53 | 2025 | 31177 | 0.650 |
Why?
|
| Hospital Mortality | 14 | 2022 | 852 | 0.640 |
Why?
|
| Osteogenesis | 7 | 2019 | 175 | 0.640 |
Why?
|
| Acidosis | 1 | 2020 | 89 | 0.630 |
Why?
|
| Societies, Medical | 9 | 2022 | 759 | 0.630 |
Why?
|
| Politics | 1 | 2020 | 92 | 0.630 |
Why?
|
| Spinal Cord Stimulation | 1 | 2019 | 8 | 0.630 |
Why?
|
| Blood Vessel Prosthesis | 6 | 2023 | 123 | 0.620 |
Why?
|
| Machine Learning | 1 | 2024 | 441 | 0.620 |
Why?
|
| Heart Arrest | 1 | 2022 | 323 | 0.610 |
Why?
|
| Blood Transfusion | 3 | 2020 | 298 | 0.610 |
Why?
|
| Reactive Oxygen Species | 2 | 2020 | 592 | 0.610 |
Why?
|
| Tissue and Organ Procurement | 6 | 2024 | 290 | 0.610 |
Why?
|
| Lower Extremity | 2 | 2014 | 407 | 0.600 |
Why?
|
| Risk Factors | 17 | 2025 | 9801 | 0.600 |
Why?
|
| Nerve Growth Factor | 1 | 2018 | 27 | 0.600 |
Why?
|
| Aged | 39 | 2025 | 22107 | 0.600 |
Why?
|
| CREB-Binding Protein | 2 | 2014 | 27 | 0.570 |
Why?
|
| Catheterization | 1 | 2018 | 176 | 0.560 |
Why?
|
| Population Surveillance | 1 | 2020 | 439 | 0.550 |
Why?
|
| Catheterization, Peripheral | 2 | 2016 | 105 | 0.540 |
Why?
|
| Nicorandil | 3 | 2021 | 11 | 0.540 |
Why?
|
| Prosthesis Design | 1 | 2019 | 309 | 0.540 |
Why?
|
| Stents | 6 | 2023 | 504 | 0.520 |
Why?
|
| Anesthesia | 2 | 2016 | 172 | 0.520 |
Why?
|
| Risk Assessment | 14 | 2024 | 3269 | 0.520 |
Why?
|
| Neurons | 5 | 2020 | 1509 | 0.520 |
Why?
|
| Thoracotomy | 3 | 2014 | 75 | 0.520 |
Why?
|
| Time Factors | 18 | 2024 | 6550 | 0.510 |
Why?
|
| Transcranial Direct Current Stimulation | 1 | 2015 | 4 | 0.500 |
Why?
|
| Femoral Artery | 3 | 2015 | 174 | 0.490 |
Why?
|
| Evoked Potentials, Motor | 1 | 2015 | 40 | 0.490 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2019 | 530 | 0.480 |
Why?
|
| Clinical Protocols | 1 | 2016 | 254 | 0.470 |
Why?
|
| Chemokines | 2 | 2015 | 227 | 0.470 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2014 | 28 | 0.460 |
Why?
|
| Cell Survival | 7 | 2017 | 1086 | 0.450 |
Why?
|
| Apoptosis | 4 | 2018 | 2489 | 0.450 |
Why?
|
| Mitochondria | 1 | 2020 | 875 | 0.450 |
Why?
|
| Heart Valve Prosthesis | 4 | 2018 | 113 | 0.440 |
Why?
|
| Hemodynamics | 5 | 2024 | 1094 | 0.440 |
Why?
|
| Motor Activity | 3 | 2014 | 684 | 0.440 |
Why?
|
| Cells, Cultured | 13 | 2021 | 4102 | 0.430 |
Why?
|
| Acute Disease | 7 | 2025 | 980 | 0.420 |
Why?
|
| Female | 55 | 2025 | 68829 | 0.420 |
Why?
|
| Multimodal Imaging | 3 | 2019 | 110 | 0.420 |
Why?
|
| Esophagus | 1 | 2015 | 251 | 0.420 |
Why?
|
| Survival Rate | 12 | 2019 | 1872 | 0.420 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2019 | 430 | 0.410 |
Why?
|
| Intermittent Claudication | 1 | 2014 | 118 | 0.410 |
Why?
|
| Astrocytes | 1 | 2014 | 197 | 0.400 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 2511 | 0.390 |
Why?
|
| Models, Cardiovascular | 2 | 2017 | 192 | 0.390 |
Why?
|
| Cardiomyopathy, Dilated | 4 | 2020 | 381 | 0.390 |
Why?
|
| American Heart Association | 3 | 2019 | 300 | 0.390 |
Why?
|
| Pulmonary Valve | 1 | 2013 | 93 | 0.380 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2019 | 541 | 0.380 |
Why?
|
| Stroke | 5 | 2024 | 1072 | 0.380 |
Why?
|
| Vascular Diseases | 2 | 2016 | 240 | 0.370 |
Why?
|
| Cause of Death | 1 | 2013 | 395 | 0.370 |
Why?
|
| Prognosis | 9 | 2022 | 3773 | 0.360 |
Why?
|
| Anesthetics | 1 | 2011 | 75 | 0.360 |
Why?
|
| Myelitis | 1 | 2012 | 98 | 0.360 |
Why?
|
| Aorta, Abdominal | 1 | 2011 | 43 | 0.360 |
Why?
|
| Adult | 33 | 2024 | 35634 | 0.350 |
Why?
|
| Axillary Artery | 3 | 2018 | 12 | 0.350 |
Why?
|
| United States | 22 | 2023 | 13913 | 0.350 |
Why?
|
| Acute Kidney Injury | 5 | 2022 | 791 | 0.350 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2013 | 482 | 0.350 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 4 | 2020 | 1000 | 0.340 |
Why?
|
| Replantation | 3 | 2019 | 31 | 0.340 |
Why?
|
| Mitral Valve Insufficiency | 5 | 2015 | 67 | 0.340 |
Why?
|
| Monitoring, Intraoperative | 3 | 2021 | 51 | 0.330 |
Why?
|
| Aortic Arch Syndromes | 1 | 2009 | 2 | 0.330 |
Why?
|
| Heart-Assist Devices | 5 | 2019 | 538 | 0.330 |
Why?
|
| Simvastatin | 3 | 2019 | 60 | 0.330 |
Why?
|
| Diverticulum | 1 | 2009 | 11 | 0.330 |
Why?
|
| Brachiocephalic Trunk | 3 | 2018 | 11 | 0.320 |
Why?
|
| Pneumonectomy | 2 | 2008 | 151 | 0.310 |
Why?
|
| Angiography | 3 | 2019 | 197 | 0.310 |
Why?
|
| Ventricular Function, Right | 2 | 2024 | 276 | 0.310 |
Why?
|
| Anastomosis, Surgical | 3 | 2019 | 150 | 0.310 |
Why?
|
| Heart | 5 | 2023 | 645 | 0.310 |
Why?
|
| Phospholipases A2, Secretory | 3 | 2014 | 12 | 0.310 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2014 | 434 | 0.310 |
Why?
|
| Cardiovascular Diseases | 3 | 2019 | 2008 | 0.310 |
Why?
|
| Regional Blood Flow | 4 | 2019 | 463 | 0.300 |
Why?
|
| Lung | 7 | 2011 | 3940 | 0.300 |
Why?
|
| Adenocarcinoma | 5 | 2018 | 893 | 0.290 |
Why?
|
| Extracorporeal Membrane Oxygenation | 3 | 2021 | 286 | 0.290 |
Why?
|
| Phosphorylation | 4 | 2018 | 1716 | 0.290 |
Why?
|
| Echocardiography | 5 | 2019 | 636 | 0.290 |
Why?
|
| Muscle, Skeletal | 2 | 2015 | 1644 | 0.290 |
Why?
|
| Thrombocytopenia | 2 | 2020 | 189 | 0.290 |
Why?
|
| Deglutition Disorders | 1 | 2009 | 133 | 0.280 |
Why?
|
| Esophageal Neoplasms | 4 | 2018 | 297 | 0.280 |
Why?
|
| Adenosine A2 Receptor Antagonists | 2 | 2006 | 9 | 0.280 |
Why?
|
| Myofibroblasts | 3 | 2018 | 121 | 0.280 |
Why?
|
| Collateral Circulation | 2 | 2019 | 18 | 0.280 |
Why?
|
| Rabbits | 8 | 2008 | 778 | 0.280 |
Why?
|
| Myocardial Ischemia | 4 | 2018 | 259 | 0.280 |
Why?
|
| Peripheral Arterial Disease | 1 | 2014 | 458 | 0.270 |
Why?
|
| Heart Failure | 7 | 2019 | 2148 | 0.270 |
Why?
|
| Principal Component Analysis | 2 | 2024 | 190 | 0.260 |
Why?
|
| Operative Time | 2 | 2019 | 124 | 0.260 |
Why?
|
| Intraoperative Care | 2 | 2022 | 46 | 0.260 |
Why?
|
| Hindlimb | 4 | 2012 | 126 | 0.250 |
Why?
|
| Suture Techniques | 5 | 2020 | 118 | 0.250 |
Why?
|
| Follow-Up Studies | 10 | 2019 | 4896 | 0.250 |
Why?
|
| Cell Culture Techniques | 3 | 2019 | 349 | 0.250 |
Why?
|
| Organ Preservation Solutions | 2 | 2023 | 45 | 0.250 |
Why?
|
| Syndrome | 3 | 2021 | 338 | 0.240 |
Why?
|
| Catheterization, Central Venous | 1 | 2006 | 104 | 0.240 |
Why?
|
| General Surgery | 2 | 2022 | 152 | 0.230 |
Why?
|
| Myocardium | 4 | 2020 | 983 | 0.230 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2013 | 1205 | 0.230 |
Why?
|
| Recombinant Proteins | 4 | 2018 | 1311 | 0.230 |
Why?
|
| Coronary Vessel Anomalies | 2 | 2016 | 33 | 0.230 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2015 | 836 | 0.230 |
Why?
|
| Norwood Procedures | 1 | 2024 | 29 | 0.230 |
Why?
|
| Length of Stay | 7 | 2020 | 1133 | 0.220 |
Why?
|
| Tissue Adhesives | 2 | 2018 | 17 | 0.220 |
Why?
|
| Coronary Vessels | 2 | 2018 | 239 | 0.220 |
Why?
|
| Toll-Like Receptor 2 | 3 | 2020 | 113 | 0.220 |
Why?
|
| Constriction | 3 | 2013 | 46 | 0.210 |
Why?
|
| Endoleak | 2 | 2023 | 16 | 0.210 |
Why?
|
| Predictive Value of Tests | 3 | 2024 | 1951 | 0.210 |
Why?
|
| Primary Graft Dysfunction | 1 | 2023 | 29 | 0.210 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2024 | 70 | 0.210 |
Why?
|
| NF-kappa B | 6 | 2020 | 666 | 0.210 |
Why?
|
| Hypoplastic Left Heart Syndrome | 1 | 2024 | 121 | 0.210 |
Why?
|
| Brain-Derived Neurotrophic Factor | 2 | 2014 | 113 | 0.210 |
Why?
|
| Aortography | 3 | 2019 | 51 | 0.210 |
Why?
|
| Drug Evaluation, Preclinical | 3 | 2018 | 171 | 0.200 |
Why?
|
| Analysis of Variance | 3 | 2019 | 1291 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2014 | 232 | 0.200 |
Why?
|
| Minimally Invasive Surgical Procedures | 4 | 2019 | 175 | 0.200 |
Why?
|
| Educational Personnel | 1 | 2022 | 12 | 0.200 |
Why?
|
| Time-to-Treatment | 2 | 2022 | 179 | 0.200 |
Why?
|
| Blotting, Western | 4 | 2018 | 1204 | 0.200 |
Why?
|
| Consensus | 3 | 2020 | 622 | 0.190 |
Why?
|
| Fibrosis | 3 | 2020 | 526 | 0.190 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2013 | 93 | 0.190 |
Why?
|
| Pleural Effusion | 1 | 2022 | 51 | 0.190 |
Why?
|
| Cohort Studies | 6 | 2020 | 5444 | 0.180 |
Why?
|
| Reoperation | 4 | 2014 | 542 | 0.180 |
Why?
|
| Renal Insufficiency | 1 | 2023 | 149 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 851 | 0.180 |
Why?
|
| Survival Analysis | 3 | 2013 | 1271 | 0.180 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2004 | 273 | 0.180 |
Why?
|
| Shock, Cardiogenic | 2 | 2020 | 60 | 0.180 |
Why?
|
| Internship and Residency | 4 | 2020 | 1058 | 0.180 |
Why?
|
| Carbon Dioxide | 3 | 2016 | 260 | 0.180 |
Why?
|
| KATP Channels | 1 | 2021 | 20 | 0.180 |
Why?
|
| Inflammation | 5 | 2014 | 2748 | 0.180 |
Why?
|
| Mentors | 1 | 2023 | 177 | 0.180 |
Why?
|
| Propensity Score | 2 | 2019 | 266 | 0.180 |
Why?
|
| Cytokines | 3 | 2014 | 2022 | 0.180 |
Why?
|
| Lipopeptides | 1 | 2020 | 13 | 0.180 |
Why?
|
| Intraoperative Complications | 2 | 2017 | 129 | 0.180 |
Why?
|
| Quality Assurance, Health Care | 2 | 2013 | 318 | 0.170 |
Why?
|
| Potassium Channels | 1 | 2021 | 149 | 0.170 |
Why?
|
| Vascular Grafting | 1 | 2020 | 13 | 0.170 |
Why?
|
| Peroxidase | 3 | 2005 | 175 | 0.170 |
Why?
|
| Interprofessional Relations | 1 | 2023 | 279 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 3 | 2013 | 1514 | 0.170 |
Why?
|
| Inflammation Mediators | 2 | 2013 | 505 | 0.170 |
Why?
|
| Cell Adhesion | 2 | 2018 | 455 | 0.170 |
Why?
|
| Incidence | 6 | 2020 | 2646 | 0.170 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2020 | 322 | 0.170 |
Why?
|
| Surgical Instruments | 1 | 2020 | 51 | 0.160 |
Why?
|
| Cell Proliferation | 4 | 2020 | 2378 | 0.160 |
Why?
|
| Tissue Donors | 3 | 2024 | 391 | 0.160 |
Why?
|
| Heart Ventricles | 4 | 2024 | 781 | 0.160 |
Why?
|
| Cardiomyopathies | 2 | 2019 | 340 | 0.160 |
Why?
|
| Aortitis | 1 | 2019 | 10 | 0.160 |
Why?
|
| Loeys-Dietz Syndrome | 1 | 2019 | 6 | 0.160 |
Why?
|
| Ultrasonography, Interventional | 1 | 2020 | 130 | 0.160 |
Why?
|
| Tricuspid Valve | 1 | 2019 | 28 | 0.160 |
Why?
|
| Patient Selection | 4 | 2019 | 660 | 0.160 |
Why?
|
| Adenosine Triphosphate | 1 | 2021 | 482 | 0.150 |
Why?
|
| Wnt Signaling Pathway | 1 | 2020 | 170 | 0.150 |
Why?
|
| Swine | 3 | 2006 | 761 | 0.150 |
Why?
|
| RNA, Neoplasm | 1 | 2018 | 82 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 1368 | 0.150 |
Why?
|
| Creatinine | 1 | 2020 | 490 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 304 | 0.140 |
Why?
|
| Documentation | 1 | 2020 | 185 | 0.140 |
Why?
|
| Education, Medical, Graduate | 2 | 2016 | 443 | 0.140 |
Why?
|
| Filamins | 1 | 2018 | 26 | 0.140 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2021 | 151 | 0.140 |
Why?
|
| Terminology as Topic | 1 | 2019 | 204 | 0.140 |
Why?
|
| ADAMTS5 Protein | 1 | 2017 | 4 | 0.140 |
Why?
|
| Drug Synergism | 1 | 2018 | 370 | 0.140 |
Why?
|
| Hemostatics | 1 | 2018 | 50 | 0.140 |
Why?
|
| Electrocardiography | 2 | 2017 | 613 | 0.140 |
Why?
|
| Surface-Active Agents | 1 | 2018 | 86 | 0.140 |
Why?
|
| Organ Preservation | 3 | 2024 | 94 | 0.140 |
Why?
|
| Cell Transdifferentiation | 1 | 2017 | 31 | 0.140 |
Why?
|
| Blood Loss, Surgical | 1 | 2018 | 96 | 0.140 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 4 | 2019 | 40 | 0.130 |
Why?
|
| Phenotype | 8 | 2020 | 3062 | 0.130 |
Why?
|
| Immunity, Cellular | 1 | 2018 | 265 | 0.130 |
Why?
|
| Transcriptome | 2 | 2020 | 875 | 0.130 |
Why?
|
| Vasodilator Agents | 1 | 2018 | 326 | 0.130 |
Why?
|
| Graft Survival | 2 | 2023 | 514 | 0.130 |
Why?
|
| Oxygen Consumption | 3 | 2016 | 672 | 0.130 |
Why?
|
| Lipopolysaccharides | 3 | 2019 | 872 | 0.130 |
Why?
|
| Sinus of Valsalva | 1 | 2016 | 10 | 0.130 |
Why?
|
| Osteoblasts | 1 | 2017 | 117 | 0.130 |
Why?
|
| Blood Pressure | 3 | 2018 | 1736 | 0.130 |
Why?
|
| Nitric Oxide | 1 | 2021 | 896 | 0.130 |
Why?
|
| Registries | 2 | 2016 | 1903 | 0.130 |
Why?
|
| Administration, Oral | 1 | 2018 | 787 | 0.130 |
Why?
|
| Perfusion Imaging | 3 | 2024 | 56 | 0.130 |
Why?
|
| Histone Deacetylases | 1 | 2018 | 212 | 0.130 |
Why?
|
| Alkaline Phosphatase | 4 | 2019 | 147 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2020 | 1327 | 0.130 |
Why?
|
| Organ Sparing Treatments | 1 | 2016 | 32 | 0.130 |
Why?
|
| Databases, Factual | 3 | 2020 | 1269 | 0.120 |
Why?
|
| Mice, Inbred C3H | 2 | 2013 | 271 | 0.120 |
Why?
|
| Heart Atria | 1 | 2016 | 129 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2020 | 503 | 0.120 |
Why?
|
| Patient Safety | 1 | 2019 | 291 | 0.120 |
Why?
|
| Glucose | 3 | 2023 | 1003 | 0.120 |
Why?
|
| Graft Rejection | 2 | 2023 | 598 | 0.120 |
Why?
|
| Biomarkers | 4 | 2022 | 3971 | 0.120 |
Why?
|
| Decompression, Surgical | 2 | 2008 | 96 | 0.120 |
Why?
|
| Interleukins | 1 | 2017 | 241 | 0.120 |
Why?
|
| Magnetic Resonance Imaging, Cine | 3 | 2024 | 186 | 0.120 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 2014 | 16 | 0.120 |
Why?
|
| Neutrophil Activation | 2 | 2005 | 80 | 0.120 |
Why?
|
| Blood Flow Velocity | 3 | 2024 | 406 | 0.110 |
Why?
|
| Case-Control Studies | 6 | 2018 | 3384 | 0.110 |
Why?
|
| Asphyxia | 1 | 2014 | 20 | 0.110 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2017 | 231 | 0.110 |
Why?
|
| Matrix Metalloproteinases | 1 | 2015 | 91 | 0.110 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2024 | 234 | 0.110 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2006 | 192 | 0.110 |
Why?
|
| Myocardial Infarction | 2 | 2016 | 1021 | 0.110 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2015 | 129 | 0.110 |
Why?
|
| Kidney Failure, Chronic | 1 | 2019 | 546 | 0.110 |
Why?
|
| Brain Ischemia | 1 | 2017 | 321 | 0.110 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2015 | 144 | 0.110 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2011 | 135 | 0.110 |
Why?
|
| Aortic Coarctation | 2 | 2006 | 83 | 0.110 |
Why?
|
| Vascular Patency | 1 | 2014 | 102 | 0.110 |
Why?
|
| Radiography | 2 | 2006 | 800 | 0.110 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2015 | 121 | 0.110 |
Why?
|
| Comorbidity | 3 | 2020 | 1551 | 0.110 |
Why?
|
| Limb Salvage | 1 | 2014 | 57 | 0.110 |
Why?
|
| Calcium-Binding Proteins | 1 | 2015 | 213 | 0.110 |
Why?
|
| Microfilament Proteins | 1 | 2014 | 128 | 0.110 |
Why?
|
| Brain Death | 2 | 2024 | 46 | 0.110 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2014 | 80 | 0.110 |
Why?
|
| Ligation | 1 | 2013 | 87 | 0.100 |
Why?
|
| Pericardium | 2 | 2011 | 54 | 0.100 |
Why?
|
| Nerve Degeneration | 1 | 2013 | 47 | 0.100 |
Why?
|
| Minocycline | 1 | 2013 | 27 | 0.100 |
Why?
|
| Oxygen | 4 | 2006 | 916 | 0.100 |
Why?
|
| Thrombosis | 2 | 2019 | 349 | 0.100 |
Why?
|
| Sleep Deprivation | 2 | 2005 | 171 | 0.100 |
Why?
|
| Polyethylene Glycols | 1 | 2018 | 612 | 0.100 |
Why?
|
| Transplantation, Autologous | 1 | 2013 | 213 | 0.100 |
Why?
|
| Consumer Health Information | 1 | 2013 | 48 | 0.100 |
Why?
|
| Vascular Stiffness | 1 | 2017 | 467 | 0.100 |
Why?
|
| Pulmonary Emphysema | 1 | 2015 | 275 | 0.100 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2015 | 260 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 184 | 0.100 |
Why?
|
| Pulmonary Edema | 3 | 2011 | 106 | 0.100 |
Why?
|
| Mice, Knockout | 3 | 2017 | 2888 | 0.100 |
Why?
|
| Specialties, Surgical | 1 | 2013 | 74 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 1274 | 0.100 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 900 | 0.090 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1686 | 0.090 |
Why?
|
| Foam Cells | 1 | 2011 | 15 | 0.090 |
Why?
|
| Warm Ischemia | 1 | 2011 | 12 | 0.090 |
Why?
|
| Lung Neoplasms | 2 | 2014 | 2344 | 0.090 |
Why?
|
| Radiation Injuries | 1 | 2012 | 135 | 0.090 |
Why?
|
| Lung Diseases | 2 | 2008 | 743 | 0.090 |
Why?
|
| Macrophages, Peritoneal | 1 | 2011 | 92 | 0.090 |
Why?
|
| Enzyme Inhibitors | 2 | 2013 | 827 | 0.090 |
Why?
|
| Interleukin-1beta | 1 | 2013 | 369 | 0.090 |
Why?
|
| Physician's Role | 1 | 2013 | 206 | 0.090 |
Why?
|
| Lipoproteins, LDL | 1 | 2011 | 127 | 0.090 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 1 | 2010 | 16 | 0.090 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2011 | 48 | 0.090 |
Why?
|
| Aged, 80 and over | 5 | 2018 | 7066 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2017 | 680 | 0.090 |
Why?
|
| Age Factors | 3 | 2020 | 3161 | 0.080 |
Why?
|
| Ventricular Function, Left | 3 | 2024 | 529 | 0.080 |
Why?
|
| United States Food and Drug Administration | 1 | 2011 | 205 | 0.080 |
Why?
|
| Neoplastic Stem Cells | 1 | 2014 | 378 | 0.080 |
Why?
|
| Cell Movement | 1 | 2014 | 950 | 0.080 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2011 | 254 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2013 | 713 | 0.080 |
Why?
|
| Mitral Valve Prolapse | 1 | 2009 | 9 | 0.080 |
Why?
|
| Bone Morphogenetic Protein 2 | 3 | 2017 | 64 | 0.080 |
Why?
|
| Surveys and Questionnaires | 3 | 2020 | 5437 | 0.080 |
Why?
|
| Heart Aneurysm | 2 | 2011 | 10 | 0.080 |
Why?
|
| Equipment Failure | 1 | 2009 | 106 | 0.080 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2012 | 443 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2023 | 7158 | 0.070 |
Why?
|
| Clinical Competence | 3 | 2020 | 1020 | 0.070 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2014 | 467 | 0.070 |
Why?
|
| Collagen | 2 | 2020 | 438 | 0.070 |
Why?
|
| Critical Illness | 1 | 2014 | 759 | 0.070 |
Why?
|
| Liver Transplantation | 1 | 2015 | 833 | 0.070 |
Why?
|
| Brain | 1 | 2020 | 2677 | 0.070 |
Why?
|
| Work Schedule Tolerance | 2 | 2005 | 43 | 0.070 |
Why?
|
| Organ Size | 2 | 2006 | 456 | 0.070 |
Why?
|
| Hypoxia | 1 | 2014 | 1087 | 0.070 |
Why?
|
| Cell Line, Tumor | 4 | 2018 | 3185 | 0.070 |
Why?
|
| Blood Preservation | 1 | 2011 | 271 | 0.070 |
Why?
|
| Atherosclerosis | 1 | 2011 | 402 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 422 | 0.070 |
Why?
|
| Heart Septal Defects | 1 | 2006 | 7 | 0.070 |
Why?
|
| Mutation | 1 | 2018 | 3706 | 0.070 |
Why?
|
| Reperfusion | 1 | 2006 | 38 | 0.070 |
Why?
|
| Europe | 2 | 2018 | 363 | 0.060 |
Why?
|
| Computed Tomography Angiography | 2 | 2018 | 115 | 0.060 |
Why?
|
| Triazines | 1 | 2006 | 38 | 0.060 |
Why?
|
| Models, Educational | 1 | 2006 | 91 | 0.060 |
Why?
|
| Hemiplegia | 1 | 2006 | 21 | 0.060 |
Why?
|
| Probability | 1 | 2006 | 304 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 1050 | 0.060 |
Why?
|
| Cardiac Catheterization | 1 | 2009 | 520 | 0.060 |
Why?
|
| Decision Making | 1 | 2013 | 864 | 0.060 |
Why?
|
| Heart Defects, Congenital | 1 | 2013 | 796 | 0.060 |
Why?
|
| Methylprednisolone | 1 | 2006 | 83 | 0.060 |
Why?
|
| Nitric Oxide Synthase | 1 | 2006 | 237 | 0.060 |
Why?
|
| Needs Assessment | 1 | 2007 | 357 | 0.060 |
Why?
|
| Blood Gas Analysis | 1 | 2005 | 73 | 0.060 |
Why?
|
| Receptors, Adenosine A2 | 1 | 2004 | 5 | 0.060 |
Why?
|
| Triazoles | 1 | 2006 | 148 | 0.060 |
Why?
|
| Virginia | 4 | 2010 | 60 | 0.060 |
Why?
|
| Intensive Care Units | 2 | 2020 | 738 | 0.060 |
Why?
|
| Actins | 2 | 2017 | 410 | 0.060 |
Why?
|
| Cardiac Output | 1 | 2005 | 157 | 0.060 |
Why?
|
| Severity of Illness Index | 4 | 2005 | 2739 | 0.060 |
Why?
|
| Random Allocation | 1 | 2005 | 347 | 0.060 |
Why?
|
| Teaching | 1 | 2006 | 218 | 0.060 |
Why?
|
| Sleep Disorders, Circadian Rhythm | 1 | 2004 | 37 | 0.060 |
Why?
|
| Models, Animal | 1 | 2006 | 376 | 0.060 |
Why?
|
| RNA Interference | 2 | 2017 | 451 | 0.050 |
Why?
|
| Recovery of Function | 1 | 2008 | 645 | 0.050 |
Why?
|
| Paraparesis | 1 | 2023 | 6 | 0.050 |
Why?
|
| Thoracic Outlet Syndrome | 1 | 2003 | 15 | 0.050 |
Why?
|
| Transfection | 2 | 2017 | 918 | 0.050 |
Why?
|
| Hospital Costs | 2 | 2010 | 115 | 0.050 |
Why?
|
| Costs and Cost Analysis | 1 | 2024 | 201 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2005 | 581 | 0.050 |
Why?
|
| Morbidity | 2 | 2020 | 302 | 0.050 |
Why?
|
| Shock | 1 | 2024 | 92 | 0.050 |
Why?
|
| Travel | 1 | 2023 | 122 | 0.050 |
Why?
|
| Vasodilation | 1 | 2006 | 476 | 0.050 |
Why?
|
| Fontan Procedure | 1 | 2024 | 175 | 0.050 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2003 | 132 | 0.050 |
Why?
|
| Antithrombins | 1 | 2022 | 58 | 0.050 |
Why?
|
| Cyanoacrylates | 1 | 2001 | 4 | 0.050 |
Why?
|
| Ulcer | 1 | 2021 | 28 | 0.050 |
Why?
|
| Glutaral | 1 | 2001 | 15 | 0.050 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2001 | 13 | 0.050 |
Why?
|
| Hematoma | 1 | 2021 | 53 | 0.050 |
Why?
|
| Contraindications | 1 | 2001 | 90 | 0.050 |
Why?
|
| Antioxidants | 1 | 2005 | 558 | 0.050 |
Why?
|
| Death | 1 | 2022 | 117 | 0.050 |
Why?
|
| Ventricular Remodeling | 1 | 2003 | 256 | 0.050 |
Why?
|
| Drainage | 1 | 2022 | 164 | 0.040 |
Why?
|
| Organ Transplantation | 1 | 2024 | 228 | 0.040 |
Why?
|
| A549 Cells | 1 | 2020 | 59 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 2045 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 1690 | 0.040 |
Why?
|
| Seizures | 1 | 2023 | 402 | 0.040 |
Why?
|
| Warfarin | 1 | 2021 | 147 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2013 | 931 | 0.040 |
Why?
|
| Aftercare | 1 | 2022 | 206 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2006 | 902 | 0.040 |
Why?
|
| Young Adult | 4 | 2018 | 12467 | 0.040 |
Why?
|
| Forecasting | 1 | 2001 | 361 | 0.040 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2019 | 44 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 1847 | 0.040 |
Why?
|
| beta Catenin | 1 | 2021 | 224 | 0.040 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2018 | 385 | 0.040 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2019 | 97 | 0.040 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2020 | 158 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2020 | 330 | 0.040 |
Why?
|
| Age Distribution | 1 | 2019 | 372 | 0.040 |
Why?
|
| Thrombectomy | 1 | 2019 | 58 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2019 | 359 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2020 | 233 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 2016 | 0.040 |
Why?
|
| Reimbursement Mechanisms | 1 | 2019 | 84 | 0.040 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2019 | 109 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2020 | 483 | 0.040 |
Why?
|
| Gelatin Sponge, Absorbable | 1 | 2018 | 5 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2022 | 532 | 0.040 |
Why?
|
| Connectin | 1 | 2018 | 31 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2018 | 2403 | 0.040 |
Why?
|
| Hemostasis, Surgical | 1 | 2018 | 22 | 0.040 |
Why?
|
| Washington | 1 | 2018 | 149 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 860 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2022 | 1877 | 0.040 |
Why?
|
| Hydroxamic Acids | 1 | 2018 | 88 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2018 | 164 | 0.030 |
Why?
|
| Matrilin Proteins | 1 | 2017 | 3 | 0.030 |
Why?
|
| Respiratory Insufficiency | 1 | 2021 | 313 | 0.030 |
Why?
|
| Patient-Specific Modeling | 1 | 2017 | 39 | 0.030 |
Why?
|
| Sp7 Transcription Factor | 1 | 2017 | 7 | 0.030 |
Why?
|
| Antagomirs | 1 | 2017 | 12 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2011 | 1160 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2019 | 216 | 0.030 |
Why?
|
| Myosins | 1 | 2018 | 134 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 1005 | 0.030 |
Why?
|
| Cross-Linking Reagents | 1 | 2018 | 207 | 0.030 |
Why?
|
| Potassium | 1 | 1997 | 144 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2018 | 399 | 0.030 |
Why?
|
| NFATC Transcription Factors | 1 | 2017 | 86 | 0.030 |
Why?
|
| Infant | 3 | 2024 | 9018 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 379 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2020 | 1501 | 0.030 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2018 | 209 | 0.030 |
Why?
|
| Marfan Syndrome | 1 | 2016 | 39 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2017 | 317 | 0.030 |
Why?
|
| Bioprosthesis | 1 | 2016 | 40 | 0.030 |
Why?
|
| Pulmonary Artery | 3 | 2011 | 1097 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2022 | 856 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2017 | 252 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2017 | 467 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 486 | 0.030 |
Why?
|
| Rats | 2 | 2018 | 5487 | 0.030 |
Why?
|
| Aminosalicylic Acids | 1 | 2014 | 5 | 0.030 |
Why?
|
| Tensins | 1 | 2014 | 5 | 0.030 |
Why?
|
| Benzenesulfonates | 1 | 2014 | 20 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2015 | 306 | 0.030 |
Why?
|
| Thrombelastography | 1 | 2015 | 150 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2016 | 306 | 0.030 |
Why?
|
| Vascular Resistance | 2 | 2011 | 371 | 0.030 |
Why?
|
| Administration, Inhalation | 2 | 2006 | 673 | 0.030 |
Why?
|
| Hydrogels | 1 | 2001 | 646 | 0.030 |
Why?
|
| In Vitro Techniques | 2 | 2006 | 1092 | 0.030 |
Why?
|
| Epidermal Growth Factor | 1 | 2014 | 170 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2015 | 173 | 0.030 |
Why?
|
| Myocytes, Cardiac | 1 | 2018 | 499 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2013 | 55 | 0.030 |
Why?
|
| Adolescent | 3 | 2023 | 20451 | 0.030 |
Why?
|
| Insulin | 1 | 2023 | 2330 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2019 | 1724 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 954 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 484 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2015 | 631 | 0.020 |
Why?
|
| Osteopontin | 1 | 2012 | 34 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 615 | 0.020 |
Why?
|
| Smoking | 1 | 2019 | 1502 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2020 | 2703 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2020 | 2274 | 0.020 |
Why?
|
| Postoperative Hemorrhage | 1 | 2012 | 88 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2012 | 185 | 0.020 |
Why?
|
| Pravastatin | 1 | 2011 | 40 | 0.020 |
Why?
|
| Emergency Treatment | 1 | 2012 | 114 | 0.020 |
Why?
|
| Heptanoic Acids | 1 | 2011 | 64 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 2135 | 0.020 |
Why?
|
| Prevalence | 1 | 2018 | 2564 | 0.020 |
Why?
|
| Hypertension | 1 | 2020 | 1242 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 925 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 1003 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2012 | 216 | 0.020 |
Why?
|
| Peptidoglycan | 1 | 2011 | 23 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 3089 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2011 | 298 | 0.020 |
Why?
|
| Culture Media | 1 | 2011 | 162 | 0.020 |
Why?
|
| Pyrroles | 1 | 2011 | 202 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 2545 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 2062 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 515 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 998 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 610 | 0.020 |
Why?
|
| Device Removal | 1 | 2009 | 136 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 1022 | 0.020 |
Why?
|
| Biopsy | 1 | 2011 | 1089 | 0.020 |
Why?
|
| Equipment Design | 1 | 2009 | 514 | 0.020 |
Why?
|
| Suicide | 1 | 2014 | 616 | 0.020 |
Why?
|
| Partial Pressure | 1 | 2006 | 30 | 0.020 |
Why?
|
| Gases | 1 | 2006 | 44 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2006 | 167 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2010 | 617 | 0.020 |
Why?
|
| Pressure | 1 | 2006 | 240 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 1989 | 0.020 |
Why?
|
| Motor Skills | 1 | 2006 | 93 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 402 | 0.010 |
Why?
|
| Hyperoxia | 1 | 2005 | 90 | 0.010 |
Why?
|
| Arteries | 1 | 2006 | 266 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 1368 | 0.010 |
Why?
|
| Algorithms | 1 | 2011 | 1617 | 0.010 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2006 | 646 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2011 | 1900 | 0.010 |
Why?
|
| Heart Function Tests | 1 | 2003 | 59 | 0.010 |
Why?
|
| Fatigue | 1 | 2005 | 319 | 0.010 |
Why?
|
| Clavicle | 1 | 2003 | 33 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2004 | 306 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2006 | 10522 | 0.010 |
Why?
|
| Proteins | 1 | 2006 | 944 | 0.010 |
Why?
|
| Stroke Volume | 1 | 2004 | 593 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2003 | 639 | 0.010 |
Why?
|
| Hypertonic Solutions | 1 | 1997 | 7 | 0.010 |
Why?
|
| Atrial Function, Left | 1 | 1997 | 7 | 0.010 |
Why?
|
| Buffers | 1 | 1997 | 56 | 0.010 |
Why?
|
| Lung Compliance | 1 | 1997 | 48 | 0.010 |
Why?
|
| Mammary Arteries | 1 | 1997 | 7 | 0.010 |
Why?
|
| Tidal Volume | 1 | 1997 | 85 | 0.010 |
Why?
|
| Dextrans | 1 | 1997 | 84 | 0.010 |
Why?
|
| Blood | 1 | 1997 | 105 | 0.010 |
Why?
|
| Hospitals, University | 1 | 1997 | 180 | 0.010 |
Why?
|
| Cryopreservation | 1 | 1997 | 94 | 0.010 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 1997 | 140 | 0.010 |
Why?
|
| Hypertension, Pulmonary | 1 | 2006 | 1897 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 1997 | 569 | 0.010 |
Why?
|
| Child | 1 | 2006 | 20962 | 0.000 |
Why?
|